{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:10:07Z","timestamp":1790554207185,"version":"4.1.0"},"reference-count":101,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode.en"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pre\u2010exposure prophylaxis (PrEP) is an important HIV prevention option. Two randomized trials have provided efficacy evidence for long\u2010acting injectable cabotegravir (CAB\u2010LA) as PrEP. In considering CAB\u2010LA as an additional PrEP modality for people at substantial risk of HIV, it is important to understand community response to injectable PrEP. We conducted a systematic review of values, preferences and perceptions of acceptability for injectable PrEP to inform global guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched nine databases and conference websites for peer\u2010reviewed and grey literature (January 2010\u2212September 2021). There were no restrictions on location. A two\u2010stage review process assessed references against eligibility criteria. Data from included studies were organized by constructs from the Theoretical Framework of Acceptability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 62 unique references. Most studies were observational, cross\u2010sectional and qualitative. Over half of the studies were conducted in North America. Men who have sex with men were the most researched group. Most studies (57\/62) examined injectable PrEP, including hypothetical injectables (55\/57) or placebo products (2\/57). Six studies examined CAB\u2010LA specifically. There was overall interest in and often a preference for injectable PrEP, though there was variation within and across groups and regions. Many stakeholders indicated that injectable PrEP could help address adherence challenges associated with daily or on\u2010demand dosing for oral PrEP and may be a better lifestyle fit for individuals seeking privacy, discretion and infrequent dosing. End\u2010users reported concerns, including fear of needles, injection site pain and body location, logistical challenges and waning or incomplete protection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Despite an overall preference for injectable PrEP, heterogeneity across groups and regions highlights the importance of enabling end\u2010users to choose a PrEP modality that supports effective use. Like other products, preference for injectable PrEP may change over time and end\u2010users may switch between prevention options. There will be a greater understanding of enacted preference as more end\u2010users are offered anti\u2010retroviral (ARV)\u2010containing injectables. Future research should focus on equitable implementation, including real\u2010time decision\u2010making and how trained healthcare providers can support choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given overall acceptability, injectable PrEP should be included as part of a menu of prevention options, allowing end\u2010users to select the modality that suits their preferences, needs and lifestyle.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.26107","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T03:11:36Z","timestamp":1689217896000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Systematic review of the values and preferences regarding the use of injectable pre\u2010exposure prophylaxis to prevent HIV acquisition"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4758-7390","authenticated-orcid":false,"given":"Lara","family":"Lorenzetti","sequence":"first","affiliation":[{"name":"Global Health and Population Research FHI 360  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-7729","authenticated-orcid":false,"given":"Nhi","family":"Dinh","sequence":"additional","affiliation":[{"name":"Global Health and Population Research FHI 360  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[{"name":"ASTRA Consulting  Kensington California USA"},{"name":"Center for AIDS Prevention Studies Department of Medicine University of California  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-3549","authenticated-orcid":false,"given":"Virginia","family":"Fonner","sequence":"additional","affiliation":[{"name":"Global Health and Population Research FHI 360  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-2830","authenticated-orcid":false,"given":"Kathleen","family":"Ridgeway","sequence":"additional","affiliation":[{"name":"Global Health and Population Research FHI 360  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rodolph","sequence":"additional","affiliation":[{"name":"World Health Organization Global HIV Hepatitis and STI Programmes  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Schaefer","sequence":"additional","affiliation":[{"name":"World Health Organization Global HIV Hepatitis and STI Programmes  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-6407","authenticated-orcid":false,"given":"Heather\u2010Marie A.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"World Health Organization Global HIV Hepatitis and STI Programmes  Geneva Switzerland"},{"name":"UNAIDS Regional Office for Asia and the Pacific  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Baggaley","sequence":"additional","affiliation":[{"name":"World Health Organization Global HIV Hepatitis and STI Programmes  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"World Health Organization. HIV data and statistics.World Health Organization;2020."},{"key":"e_1_2_13_3_1","unstructured":"World Health Organization.Guideline on when to start antiretroviral therapy and on pre\u2010exposure prophylaxis for HIV.Switzerland:World Health Organization;2015."},{"key":"e_1_2_13_4_1","unstructured":"HIV\/AIDS JUNPo. Danger: UNAIDS Global AIDS Update 2022.2022."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.08.001"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824a060b"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2009.0021"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31826f9962"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3463-4"},{"key":"e_1_2_13_12_1","unstructured":"World Health Organization.Guidelines: updated recommendations on HIV prevention infant diagnosis antiretroviral initiation and monitoring.Switzerland:World Health Organization;2021."},{"issue":"22","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2018.18947","article-title":"PrEP disparities","volume":"320","author":"Kuehn B","year":"2018","journal-title":"JAMA"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0242"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01143-8"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224898"},{"key":"e_1_2_13_17_1","first-page":"8","article-title":"Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084","volume":"24","author":"Delany","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_2_13_20_1","unstructured":"FDA approves first injectable treatment for HIV pre\u2010exposure prevention [press release].U.S. Food and Drug Administration;2021."},{"key":"e_1_2_13_21_1","volume-title":"Guidelines on long\u2010acting injectable cabotegravir for HIV prevention","author":"WHO","year":"2022"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003494"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-010-0319-7"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2004.010322"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2031-8"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03796-1"},{"key":"e_1_2_13_28_1","unstructured":"Joanna Briggs Institute. Critical Appraisal Tools.University of Adelaide Australia; Joanna Briggs Institute."},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114700"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2015.0143"},{"key":"e_1_2_13_31_1","unstructured":"MeyersK GolubSA.To switch or not to switch: anticipating choices in biomedical HIV prevention.HIV Research for Prevention; October 17\u201321 2016;Chicago IL;2016."},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1071\/SH15144"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1370-5"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1565-9"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000678"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/lgbt.2017.0244"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-017-1049-7"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0214"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1996-y"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1907-2"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-2017-x"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1871-x"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1845-z"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1511346"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209484"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2018.1557590"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0093"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16142620"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25528"},{"key":"e_1_2_13_50_1","unstructured":"TorresTS KondaKA Vega\u2010RamirezEH ElorreagaOA Diaz\u2010SosaD HoaglandB et\u00a0al.MSM at high HIV risk in Latin America prefer long\u2010acting PrEP.23rd International AIDS Conference; July 6\u201310 2020; Virtual2020."},{"issue":"1","key":"e_1_2_13_51_1","first-page":"32","article-title":"Preferences for pre\u2010exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study","volume":"8","author":"Gutierrez JI","year":"2021","journal-title":"Mil Med Res"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13178-020-00441-1"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25664"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06178-5"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.19.1.20875"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0075"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2078-5"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17729376"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002215"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25408"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-020-01834-4"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2020.0164"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03023-9"},{"key":"e_1_2_13_64_1","unstructured":"TolleyEE BulaA ChitukutaM EtimaJ KhozaN NameyE et\u00a0al. Acceptability of injectable versus daily oral pills for HIV prevention: lesson from HPTN 084 IAS 20222022."},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.3.19157"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001960"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2018.10.209"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2019.09.016"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1742861"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200296"},{"key":"e_1_2_13_71_1","unstructured":"SlamaL PorcherR ChakvetadzeC CrosA LinardF GallardoL et\u00a0al.Injectable long acting antiretroviral for HIV treatment or prevention: the ANRS CLAPT study.17th European AIDS Conference; November 6\u20139 2019;Basel Switzerland;2019."},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1742869"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02703-5"},{"key":"e_1_2_13_74_1","unstructured":"AppenrothM CastellanosE.Key populations' values and preferences for HIV hepatitus and STI services: a qualitative study.New York:GATE;2021."},{"key":"e_1_2_13_75_1","unstructured":"Ashodaya Samithi.Community listening exercise on PrEP: a report to assess community understanding and desires in accessing and using new prevention products for HIV prevention.Karnataka;2021."},{"key":"e_1_2_13_76_1","unstructured":"PoteatT van derMerweLLA CloeteA AdamsD MalikM WirtzA.Preferences for PrEP formulations and service delivery: results from qualitative in\u2010depth interviews with transgender women in three South African cities.HIV Research for Prevention; January 27\u201328 and February 3\u20134 2021; Virtual2021."},{"key":"e_1_2_13_77_1","unstructured":"Tagliaferri RaelC Lopez\u2010RiosJ McKennaS BocktingW DolezalC DasD et\u00a0al.Transgender women's perspectives on streamlined strategies to administer long\u2010acting injectable PrEP: recommendations for product development.HIV Research for Prevention; January 27\u201328 and February 3\u20134 2021; Virtual2021."},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1521\/aeap.2019.31.4.363"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1810616"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1587356"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1587352"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02767-3"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108058"},{"key":"e_1_2_13_84_1","unstructured":"International Network of People Who Inject Drugs (INPUD).Excerpt from INPUD\/WHO Key Populations Values & Preferences for HIV Hepatitis & STI Services Report 2021.2022."},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2018.1488027"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7276-1"},{"key":"e_1_2_13_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02418-7"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09785-0"},{"key":"e_1_2_13_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02808-2"},{"key":"e_1_2_13_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001945"},{"key":"e_1_2_13_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1972-6"},{"key":"e_1_2_13_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2022.04.011"},{"key":"e_1_2_13_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04008-0"},{"key":"e_1_2_13_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25502"},{"key":"e_1_2_13_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001536"},{"key":"e_1_2_13_96_1","unstructured":"Gilead announces first global regulatory approval of Sunlenca\u00ae (Lenacapavir) the only twice\u2010yearly HIV treatment option [press release].Foster City CA:Gilead Sciences Inc.;2022."},{"key":"e_1_2_13_97_1","unstructured":"GrinsztejnB WangZ DonnellD RichardsonP SullivanP EshlemanS et\u00a0al.EPLBC04 transgender women (TGW) in HPTN 083: an evaluation of safety efficacy and gender affirming hormonal therapy (GAHT) interactions with long\u2010acting cabotegravir (CAB\u2010LA).The 24th International AIDS Conference; 29 July\u20132 August 2022;Montreal Canada & Virtual;2022."},{"key":"e_1_2_13_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000596"},{"key":"e_1_2_13_99_1","unstructured":"AVAC.MOSAIC \u2010 Maximizing Options to Advance Informed Choice for HIV Prevention.PrEP Watch;2022."},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1627-z"},{"key":"e_1_2_13_101_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S185712"},{"key":"e_1_2_13_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001343"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.26107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:07:29Z","timestamp":1743890849000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.26107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":101,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/jia2.26107"],"URL":"https:\/\/doi.org\/10.1002\/jia2.26107","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e26107"}}